Advertisement
week in cancer news
  • October 20: The Week in Cancer News

    Immunotherapy drug approved as pre- and post-surgery treatment for non-small cell lung cancer, and bladder cancer patients who respond to chemotherapy and immunotherapy can forgo surgery.

    by Thomas Celona

  • October 13: The Week in Cancer News

    Rising prevalence of non-melanoma skin cancer leads to more deaths across the globe, and siblings of cancer patients struggle to ask for help.

    by Eric Fitzsimmons

  • October 6: The Week in Cancer News

    Minority groups less likely to receive palliative care, and radiation oncology meeting focuses on shorter radiation courses.

    by Marci A. Landsmann

  • September 29: The Week in Cancer News

    Cancer drug shortages affect pediatric care, and ‘power dynamics’ limit women’s access to cancer care globally.

    by Kevin McLaughlin

  • September 22: The Week in Cancer News

    Study links proper dental hygiene to increased survival in head and neck cancer, and researchers use breast milk to detect breast cancer in new mothers.

    by Thomas Celona

  • September 15: The Week in Cancer News

    New report charts progress in cancer care, and immediate access to test results can lead to confusion.

    by Eric Fitzsimmons

  • September 8: The Week in Cancer News

    Research shows an increase in late-stage prostate cancer diagnosis, and many non-English speakers don’t make it past helplines to access services.

    by Marci A. Landsmann

  • September 1: The Week in Cancer News

    Regulators reverse course on a plan to limit compensation for breast reconstruction surgery, and a cancer drug is among 10 selected for price negotiations with Medicare to lower costs.

    by Kevin McLaughlin

  • August 25: The Week in Cancer News

    Study finds association between lorazepam use and poorer cancer outcomes, and weight-loss surgery linked to lower cancer risk in women.

    by Thomas Celona

  • August 18: The Week in Cancer News

    Radiation therapy is falling out of favor for some cancer types, and concerns grow about commercially available multi-cancer detection tests.

    by Eric Fitzsimmons